Campos-Murguía A, Román-Calleja BM, González-Regueiro JA, Hurtado-Díaz-de-León I, Solís-Ortega AA, Flores-García NC, García-Juárez I, Ruiz-Margáin A, Macías-Rodríguez RU. Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. World J Gastroenterol 2021; 27(33): 5502-5519 [PMID: 34588748 DOI: 10.3748/wjg.v27.i33.5502]
Corresponding Author of This Article
Ricardo Ulises Macías-Rodríguez, MD, MSc, PhD, Assistant Professor, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Col. Belisario Domínguez Sección XVI, Mexico City 14080, Mexico. ricardomacro@yahoo.com.mx
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 7, 2021; 27(33): 5502-5519 Published online Sep 7, 2021. doi: 10.3748/wjg.v27.i33.5502
Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19
Alejandro Campos-Murguía, Berenice M Román-Calleja, José A González-Regueiro, Ivonne Hurtado-Díaz-de-León, Alberto Adrián Solís-Ortega, Nayelli C Flores-García, Ignacio García-Juárez, Astrid Ruiz-Margáin, Ricardo Ulises Macías-Rodríguez
Alejandro Campos-Murguía, Berenice M Román-Calleja, José A González-Regueiro, Ivonne Hurtado-Díaz-de-León, Alberto Adrián Solís-Ortega, Nayelli C Flores-García, Ignacio García-Juárez, Astrid Ruiz-Margáin, Ricardo Ulises Macías-Rodríguez, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14080, Mexico
Astrid Ruiz-Margáin, Ricardo Ulises Macías-Rodríguez, Liver Fibrosis and Nutrition Lab (LFN-Lab), MICTLÁN-Network (Mechanisms of Liver Injury, Cell Death and Translational Nutrition in Liver Diseases- Research Network), Mexico City 14080, Mexico
Author contributions: Campos-Murguía A and Román-Calleja BM contributed equally to this article; Ruiz-Margáin A and Macías-Rodríguez RU contributed equally to the study conception and design; All authors contributed to acquisition of data, analysis of data, interpretation of data, drafting the article, making critical revisions for the content of the manuscript, writing and approving the final version of the article to be published.
Conflict-of-interest statement: The authors declare that they have no conflicting interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ricardo Ulises Macías-Rodríguez, MD, MSc, PhD, Assistant Professor, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Col. Belisario Domínguez Sección XVI, Mexico City 14080, Mexico. ricardomacro@yahoo.com.mx
Received: January 28, 2021 Peer-review started: January 28, 2021 First decision: May 2, 2021 Revised: May 17, 2021 Accepted: August 5, 2021 Article in press: August 5, 2021 Published online: September 7, 2021
Core Tip
Core Tip: The coronavirus disease 2019 (COVID-19) pandemic arrived amid a population increasingly affected by metabolic diseases such as type 2 diabetes mellitus and metabolic-associated fatty liver disease (MAFLD). Patients with MAFLD can have chronic inflammation, endothelial dysfunction, and increased expression of angiotensin-converting enzyme 2 receptor, which could synergize with severe acute respiratory syndrome coronavirus 2 pathophysiology, predisposing to a greater risk of adverse outcomes. Interestingly a high prevalence of liver steatosis in postmortem samples of patients who had COVID-19 has been found. Moreover, the presence of liver fibrosis has been shown to worsen prognosis in those patients. As a result, all patients with COVID-19 should be assessed for the presence of these comorbidities and closely follow-up.
